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ABSTRACT
It is known that disorders in apoptosis function play an important role in the pathogenesis of
many types of cancer, including lung cancer. Tumor necrosis factor related apoptosis inducing
ligand (TRAIL), a type II transmembrane protein, is a death ligand capable of inducing apoptosis
by activating distinctive death receptor. Our purpose in this study is to investigate the gene
polymorphisms in TRAIL molecular pathway and TRAIL gene expression levels in non-small cell
lung cancer (NSCLC) patients in terms of pathogenesis and prognosis of the disease. In this
study, TRAIL C1595T polymorphism was genotyped using polymerase chain reaction-restriction
fragment length polymorphism analysis in 158 patients with NSCLC and 98 healthy individuals.
Surgically resected tissues were examined and classified histopathologically. In addition, TRAIL
gene expression levels in tumor tissue and tumor surrounding tissue samples of 48 patients
with NSCLC were determined using real-time polymerase chain reaction. TRAIL gene expression
levels of NSCLC patients were detected significantly 28.8 fold decrease in the tumor tissue
group compared to the control group (p=0.026). When patients were compared to tumor stage,
expression of TRAIL gene in advanced tumor stage was found to be significantly 7.86 fold
higher than early tumor stage [p=0.028]. No significant relationship was found between NSCLC
predisposition and prognostic parameters of NSCLC with TRAIL genotypes, but the frequency of
TRAIL gene 1595 CT genotype was observed to be lower in the patients compared to the other
genotypes, and the difference was found to be very close to statistical significance (p=0.07). It
can be suggested that TRAIL may play an important role in the development of NSCLC and may
be an effective prognostic factor in tumor progression.: It is known that disorders in apoptosis
function play an important role in the pathogenesis of many types of cancer, including lung
cancer. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a type II transmem-
brane protein, is a death ligand capable of inducing apoptosis by activating distinctive death
receptor. Our purpose in this study is to investigate the gene polymorphisms in TRAIL
molecular pathway and TRAIL gene expression levels in non-small cell lung cancer (NSCLC)
patients in terms of pathogenesis and prognosis of the disease.
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Lung cancer is the leading cause of cancer deaths in
men andwomen all over the world [1]. Lung cancers can
be divided into two major histological types, as non-
small cell lung cancer (NSCLC) and small cell lung can-
cer. They behave differently in terms of biologically and
sensitivity to chemotherapy and radiotherapy [2,3].
NSCLC is responsible for 80–85% of lung cancer patients
and is divided into squamous cell carcinoma, adenocar-
cinoma, and large cell carcinoma subtypes based on
histological features [4]. Lung cancer frequency is
depended on many factors such as smoking, passive
smoking, occupational and environmental factors,
genetic susceptibility, age, gender, and ethnicity [2].
Parameters effecting NSCLC prevalence include envir-
onmental and genetic factors, abnormalities in growth
factor signaling pathways and tumor suppressor gene
pathways, apoptosis escape and epigenetic modifica-
tion mechanisms [5]. It has also been confirmed that
genetic mechanisms such as gene mutation, deletion,
and polymorphism determine the susceptibility of dif-
ferent individuals to lung cancer [6]. In recent years,
studies have been carried out at the molecular level to
reveal the pathogenesis of lung cancers [5]. Death
ligands that can cause apoptosis through cell surface
death receptors are also one of the molecules studied.
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Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is type II transmembrane protein that is
a member of tumor necrosis factor family [7,8]. It selec-
tively triggers apoptosis in cancer cells, while TRAIL does
not affect normal cells [9–11]. Five TRAIL receptors have
been identified: TRAIL-R1 (death receptor 4 – DR4),
TRAIL-R2 (DR5/KILLER), TRAIL-R3 (decoy receptor 1 –
DcR1/TRID), TRAIL-R4 (DcR2/TRUNDD), and osteoprote-
gerin (OPG). TRAIL may induce or inhibit apoptosis
depending on the receptor type that is bounded.
TRAIL-R1 and TRAIL-R2 contain cytoplasmic death
domain and induce apoptosis after ligand binding. The
death domain of TRAIL-R3, TRAIL-R4, and OPG is either
truncated or lack and cannot induce apoptosis [8,12,13].
TRAIL has been shown to be expressed at the protein
and mRNA level in different tissue such as liver, lung,
placenta, kidney, spleen, heart, ovary, small and large
intestine, and also in several cells, including immune
cells [14–16].
The TRAIL gene located on chromosome 3q26 is
approximately 20 kb in length [17,18], and this gene
which encodes an mRNA of 1.77 kb is composed of 5
exons and 4 introns [12,13]. Despite the fact that
polymorphisms of TRAIL have been reported in var-
ious cancers such as lung cancer [6], colon cancer [12],
breast cancer [13,19], gastric cancer [20], bladder can-
cer [21], prostate cancer [22], and renal cancer [23], in
some diseases such as type 2 diabetes mellitus [24],
intervertebral disc disorder [25], multiple sclerosis
[26], ulcerative colitis [27], and fatty liver disease
[28]. However, the role of TRAIL polymorphism in
lung cancer is yet to be elucidated [29].
In a study of 592 patients with NSCLC, Luo et al.
found that the CT + TT mutant genotype of the TRAIL
C1595T variant was lower in the NSCLC group than in
the control group, but this result was not statistically
related. T mutant allele frequency was found to be
significantly higher in patients with NSCLC [6]. The
expression of apoptosis-inducing ligands such as
TRAIL has been suggested to play an important role
in cell regulation and may provide an immunological
advantage for tumor cells [4]. TRAIL have determined is
expressed by 91% of patients with NSCLC in immuno-
histochemical-based studies [3,4]. Spierings et al. have
determined immunohistochemically low TRAIL expres-
sion in 9% of NSCLC samples and high TRAIL expres-
sion in 59% of NSCLC samples in 87 stage III NSCLC
patients [4]. As also stated in the article of Luo et al., in
an immunohistochemical study performed in 60 NSCLC
tissue, the positive staining rate of TRAIL protein was
found to be significantly lower in the tumor tissue
compared to the adjacent normal tissue [6].
The influence of the 3ʹUTR region on gene regula-
tion is a key mechanism and it is expressed that the
polymorphism in position 1595 of the TRAIL gene may
be a factor that can regulate the protein by altering
the microRNA binding sequence of TRAIL [28].
In our study, it was aimed to determine genotype
and allele frequencies by examining the gene poly-
morphisms on TRAIL, one of the important molecules
in apoptosis pathway in patients with NSCLC and to
investigate TRAIL gene expression levels. It was also
aimed to determine whether these genotype and
allele frequencies and TRAIL gene expression levels
were correlated with the histopathological para-
meters of the disease. As a result of the obtained
data, it will be evaluate whether a possible association
between gene polymorphisms of the TRAIL molecular
pathway and TRAIL gene expression levels in patients
with NSCLC is effective on the pathogenesis and
prognosis of the disease.
2. Methods
2.1. Subjects
In our study, peripheral blood samples of 158 patients,
27 female and 131 male, who were diagnosed as NSCLC
at the Department of Thoracic Surgery, Cerrahpasa
Medical Faculty, Istanbul University were taken and
tumor tissue and tumor surrounding tissue samples of
48 patients (n = 11(%22.2) female, n = 37(%77.8) male)
were resected. Our work was carried out by the Ethics
Committee of Istanbul University Cerrahpaşa Medical
School with the permission number 219543.
2.2. Genotyping
DNA isolation was performed by salting out peripheral
blood samples from NSCLC patients and healthy sub-
jects [30]. For the TRAIL C1595T polymorphism the for-
ward primer 5ʹ-TGA GCA CTA CAG CAA ACA TGA-3ʹ and
reverse primer 5ʹ-GCA CCA CTA AAA GAT CGC AGT-3ʹ
were used at a concentration of 10 pmol/μl for each
primer. The PCR reaction mixture contained 150 ng
DNA template, 1.75 mM MgCl2, 50 mMKCl, 10 mM Tris-
HCl[pH 8.4], 600 μM dNTP (iNtRON Biotechnology Co.,
Korea) and 0.06 unit Taq DNA polymerase (iNtRON
Biotechnology Co., Korea). The PCR conditions were
determined as first denaturation at 95°C for 5 min, 35
cycles at 94°C for 45 s, 58°C for 45 s, 72°C for 45 s, and a
final extension at 72°C for 5 min. PCR product was
digested by RsaI(MBI Fermentas, CA) at 37°C for 2.5 h.
After enzymatic restriction, two fragments having 59
and 332 bp(C allele) or three fragments having 59, 146,
and 186 bp(T allele) were identified.
2.3. Gene expression
Tumor tissue and the tumor surrounding tissue samples
were surgically dissected. Samples were stored in liquid
nitrogen until use. Total RNA was isolated from tissues
using the TRIzol method. cDNA synthesis from total RNA
was performed by using the High-Capacity cDNA Reverse
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Transcription Kit (LifeTech, Applied Biosystem, USA). As a
result of our literature researches and pilot studies, it was
determined that GAPDH gene is suitable as housekeep-
ing gene. PCR primers and probes for the TRAIL and
GAPDH gene were selected using the Single Tube
TaqMan Gene Expression Assay (LifeTech, Applied
Biosystem, USA). The real-time PCR reaction mixture con-
tained 100 ng cDNA, 2X PZR Master Mix (LifeTech,
Applied Biosystem, USA) and 20X Primer and Probe
ready mix (LifeTech, Applied Biosystem, USA) for both
primers. Real-time PCR conditions were determined as
UDG incubation at 50°C for 2 min, AmpliTaq Gold
UP enzyme activation at 95°C for 10 min, and 40 cycles
at 95°C for 15 s and at 60°C for 1 min. Real-time PCR
analysis was performed using Stratagene Mx3005p
instrument (Agilent Technologies, CA, USA) with
TaqMan Gene Expression Master Mix (LifeTech, Applied
Biosystem, USA).
2.4. Statistical analysis
In our study, Chi square and further tests were applied
by using SPSS 7 package program for statistical ana-
lysis of TRAIL C1595T variant, TRAIL gene expression
values, demographic data, and histopathological para-
meters. The variables of statistically significant differ-
ence in the univariate analysis were then introduced
into the multivariate analysis. Mann–Whitney U test,
which is one of the non-parametric tests, was applied
by using GraphPad Prism 5 program for the statistical
analysis of gene expression levels of tumors and con-
trol tissues. The data were verified with both statistical
programs. p values that are lower than 0.05 were
regarded as statistically significant.
3. Results
3.1. TRAIL C1595T polymorphism genotype and
allele distributions
In our study, we examined TRAIL C1595T polymorph-
ism in 158 NSCLC patients and 98 control groups. The
genotype and allele frequencies of the TRAIL C1595T
variant in NSCLC patients and controls are shown in
Table 1. In our study, when the heterozygous CT
genotype of the TRAIL C1595T variant was compared
to the homozygous CC and TT genotypes, the
frequency of CT genotype carriers in the patient
group was found to be lower than that of the control
group and this difference was detected to be close to
statistically significance (p = 0.07). Although TRAIL
C1595T homozygous CC and TT genotype ratios
were higher in patients than control and heterozy-
gous CT genotype ratios were lower, there was no
statistically significant difference between patient and
control groups in terms of genotype distribution of
C1595T variant (p = 0.24). There was no statistically
significant difference between patient and control
groups in terms of C allele carrier of the TRAIL gene
C1595T variant (p = 0.28). Although the T allele fre-
quency was lower in patients with NSCLC than in the
control group, the difference between patient and
control group was not statistically significant
(p = 0.15). In addition, it can be stated that the T allele
carrier may lead to about nearly twice the risk
increase in terms of mutation presence (Fisher’s
Exact test, p = 0.297). The distribution of TRAIL
C1595T genotypes according to clinical parameters
and tumor characteristics of patients with NSCLC is
shown in Table 2. When the genotype and allele
distributions of TRAIL C1595T variant were examined
according to the histopathological findings of NSCLC
patients, perinural invasion, lymphatic invasion, vas-
cular invasion, lymph node metastasis, tumor stage,
and metastasis of distant organs were not associated
with genotype. We found no statistically significant
difference between genotype and allelic distribution
and gender with respect to multivariate analysis
(p > 0.05).
3.2. TRAIL gene expression
The gene expression levels of TRAIL were determined
using the ΔΔCt method. A calibrator was established
to normalize the obtained ΔΔCt value. Separate cali-
brators were used for each group because of the
heterogeneous distribution of tumor tissue group
and tumor surrounding tissue group values of
NSCLC patients. Calibrator selection was done take
notice of data such as geometric and arithmetic
Table 1. Genotype and allele frequencies of TRAIL C1595T
variant in patients with NSCLC and controls.
Genotypes and alleles Patients n (%) Controls n (%) p Value
Genotype
CC 99 (62.7) 55 (56.1) 0.24
CT 43 (27.2) 36 (36.7)
TT 16 (10.1) 7 (7.1)
Allele
C Allele 241 (76.3) 146 (74.5) 0.65
T Allele 75 (23.7) 50 (%25.5)
n: number of individuals
Table 2. Genotypic distribution of TRAIL C1595T variant
according to histopathological findings of NSCLC patients.
Histopathological




N123 30 (65.2) 11 (23.9) 5 (10.9) 0.638
N0 36 (58.1) 20 (32.3) 6 (9.7)
Tumor stage
T3 + T4 21 (61.8) 11 (32.4) 2 (5.9) 0.567
T1 + T2 45 (60.8) 20 (27.0) 9 (12.2)
Metastasis
No 65 (62.5) 28 (26.9) 11 (10.6) 0.110
Yes 1 (25.0) 3 (75.0) 0 (0.0)
n: number of individuals.
Some histopathological data obtained from our patients could not be
reached.
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mean and lowest Ct value except for cases with exces-
sive gene expression values. The value of the calibra-
tor sample is fixed at 1. The value selected as the
calibrator was used for normalization only, not includ-
ing statistical analysis. Relative quantitation levels
were obtained from normalized Ct values and the
tumor tissue group and the tumor surrounding tissue
group were evaluated separately and compared with
each other. In our study, TRAIL gene expression levels
were determined from a total of 48 tumor tissues and
tumor surrounding tissue samples. We were revealed
that the TRAIL gene expression levels expressed 28,8
times lower in the tumor tissue group than that of the
control tissue group and this difference was statisti-
cally significant (p = 0.026) (Figure 1). According to
the fold change values of TRAIL gene expression
levels as regards the control tissue of tumor tissues
of our cases, while high TRAIL gene expression levels
were observed in 16.6% of cases, low TRAIL gene
expression levels were detected in 83.3% of cases.
When TRAIL gene expression levels were compared
with tumor stage, one of the histopathological para-
meters, we were revealed that the TRAIL gene
expression levels were 7.86 times higher in the
advanced tumor stage (T3/T4) than in the early
tumor stage (T1/T2)(p = 0.028). The data related to
the comparison of demographic characteristics and
histopathological parameters of TRAIL gene expres-
sion levels are given in Table 3. In our study, no
significant difference was found between TRAIL gene
expression levels and genotype and allele distribution
of TRAIL C1595T variant (p > 0.05).
4. Discussion
Lung cancer is a major health problem all over the
world, with more than 1.8 million new cases being
diagnosed each year and loss of about 1.6 million of
these cases [31–33]. With the NSCLC being a multi-
factorial disease with associated to genetic risk, life-
style and environmental exposure risk [34], no
mechanism alone can fully explain all aspects of
NSCLC. Tumorigenesis in NSCLC is related to espe-
cially the p53, k-ras, and EGFR genes, which are seen
in different forms of mutation and different frequen-
cies among non-smokers and smokers [6].
Studies have shown that the 3ʹ-UTR region of exon
5 of TRAIL plays an important role in regulation of the
TRAIL gene [6,24,35]. The 3ʹ-UTR, which functions as a
regulatory region at the level of protein expression,
binds not only to mRNA but also to mRNA coated
with RNA proteins [RBPs] and microRNAs (miRNAs),
which play important roles in the regulation of trans-
lation [24,36]. Studies have suggested that an allelic
variation which changes the level of expression of
the protein in the genome of patients, particularly in
the 3ʹ-UTR, plays an important role in the outcome of
the disease [36]. Therefore, in recent studies, the
effect of TRAIL gene SNPs on NSCLC sensitivity is









Figure 1. Comparison of expression levels of TRAIL gene in the tumor tissue group and the control tissue group.
Table 3. Comparison of TRAIL gene expression levels with






Male 7.64 ± 5.19
Female 2.34 ± 1.06
Smoking status (Package/Year)
Age ≤ 50 years 2.24 ± 0.5
Age > 50 years 12.02 ± 9.28
Alcohol intake
Yes 8.53 ± 6.76
No 3.21 ± 0.62
Tumor subtype
Squamous cell carcinoma 17.54 ± 15.73
Adenocarcinoma 2.53 ± 0.71
Lymph node metastasis
Yes 7.38 ± 5.23
No 3.93 ± 0.91
Tumor stage
T1–T2 1.92 ± 0.52*
T3–T4 15.10 ± 11.20*
Metastasis
Yes 0
No 6.32 ± 3.90
n: number of individuals; the values in the table are given as X ± SD;
*p = 0.028.
4 Ö. KOÇ ERBAŞOĞLU ET AL.
mechanism of TRAIL-induced apoptosis and down-
stream factors [6].
Luo et al. found that the CT + TT mutant genotype
of the TRAIL C1595T variant was lower in group with
NSCLC than the control group, but is not statistically
significant, and that the frequency of T mutant allele
was significantly higher in patients with NSCLC. In
conclusion, Luo et al. reported that T allele presence
may play a role in NSCLC susceptibility [6]. Our results
which are statistically insignificant are consistent in
terms of the CT + TT mutant genotype with this result
reported by Luo et al. In this study, the CT genotype
frequency of the C1595T variant was lower than the
CC + TT genotypes in patients with NSCLC compared
to controls, and this data was found to be very close
to statistical significance (p = 0.07). This result sug-
gests that in CT genotype of C1595T variant for NSCLC
patients seems to be a protective factor for lung
cancer risk. According to the results of previous stu-
dies, homozygous or heterozygous genotypes of
TRAIL C1595T variant in different cancer types appear
to have different frequencies between patients and
controls. Wang et al. found that the T allele frequency
of the TRAIL C1595T variant was significantly lower in
patients with gastric cancer than controls [20]. Timirci-
Kahraman et al. found that the frequency of TRAIL
1595 TT genotype was lower in bladder cancer
patients than in healthy controls, and the frequency
of CT genotype was significantly higher [21]. Yaylım
et al. in patients with colorectal cancer [12] and Yıldız
et al. in patients with breast cancer [13] did not find
any significant difference in TRAIL C1595T genotype
distribution. In our study, we have considered the
frequency of this genotype and alleles in Turkish
cases.
In our study, we did not detect any statistical sig-
nificance between TRAIL C1595T polymorphism and
the clinical features of NSCLC patients. When we
conducted a comprehensive literature review to
examine the effect of TRAIL gene polymorphisms on
demographic characteristics and histopathologic
parameters of patients, we found that TRAIL poly-
morphisms in general were not a significant effect
on these variables. However, in some studies it was
predicated that TRAIL gene variants have an effect on
the stage, grade or severity of the disease. Luo et al.
found that the frequencies of CT+ TT genotype and T
allele of the C1595T variant in Han Chinese cases was
significantly higher in stage III and IV NSCLC than in
stage I and II patients and Investigators have sug-
gested that at least the C1595T variant of these results
may be associated with the lesion severity and prog-
nosis of NSCLC [6]. In our study, although not statis-
tically significant, the C1595T CT + TT genotype and T
allele frequency were lower in stage III and IV NSCLC
patients than that of found in stage I and II patients
(frequencies of CT+ TT genotype: 29.4% and 39.2%, T
allele: 26.5% and 39.2%, respectively), and our results
are inconsistent with the results of Luo et al. When we
approach this issue as general carcinogenesis, Wang
et al. found that the frequency of TRAIL C1595T
variant T carriage in patients with poorly differen-
tiated gastric adenocarcinoma was significantly
lower [20]. Yaylım et al. found that TRAIL C1595T CC
and homozygous CC + TT genotypes frequency were
significantly higher in patients with advanced stage
tumors of colorectal cancer than in patients with early
stage tumors [12]. Yildiz et al. detected TRAIL C1595T
CT genotype at a significantly lower frequency in
patients with advanced stage tumor than those with
early stage tumor in breast cancer [13]. The formation
of a codominant phenotype as both dominant and
recessive with the contribution of both alleles is rele-
vant for many genes. In this context, we think that the
heterozygous carrier of the relevant variant of TRAIL
may be important in Turkish Population.
In our study, it was found that TRAIL gene expres-
sion levels were 28.8 times lower in the tumor tissue
group than in the control tissue group (p = 0.026).
According to the control tissue of the tumor tissue,
16.6% of the cases were detected high TRAIL gene
expression levels, while 83.3% of cases were observed
low TRAIL gene expression levels. This conclusion
supports the idea that the apoptosis mechanism of
patients with NSCLC may impair functioning of the
TRAIL molecular pathway. When TRAIL gene expres-
sion levels were examined in terms of tumor stage,
which is one of the prognostic parameters, TRAIL
gene expression level was 7.86-fold higher in
advanced tumor stage (T3/T4) than early tumor
stage (T1/T2)(p = 0.028). This result suggests that
TRAIL may be important for the prognosis and survi-
val of NSCLC. However, we did not analyze the survi-
val in terms of TRAIL genotypes.
Spierings et al. have found immunohistochemically
low TRAIL expression in 9% of NSCLC samples and
high TRAIL expression in 59% of NSCLC samples in 87
stage III NSCLC patients and that poorly differentiated
tumor areas of NSCLC patients exhibit a strong stain-
ing pattern for TRAIL [4]. Luo et al. indicated that the
genetic polymorphisms and haplotypes of TRAIL gene
correlated significantly with the NSCLC susceptibility
in the group of Chinese patients [6]. Although these
results and the results of our study are supportive of
each other, it is necessary to confirm these results
with another molecular biologically supported work
because it is an immunohistochemical-based study.
Macher-Goeppinger et al. found that TRAIL immuno-
histochemically expressed at high levels in 7% and
low levels in 93% of renal cell carcinoma patients
and when performing quantitative PCR analysis to
patients at group with high TRAIL immunohistochem-
istry score, have confirmed the result of immunohis-
tochemical analysis by detecting high TRAIL mRNA
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expression level [23]. Piras-Straub et al. found that
TRAIL mRNA expression was significantly lower in
66% of all hepatocellular carcinoma tissues than
tumor surrounding tissues, 11% showed equivalent
TRAIL expression, and 23% showed higher TRAIL
expression levels. They have also shown that TRAIL
expression is significantly associated with high-grade
or advanced stage tumors. In conclusion, they
declared that TRAIL is an important factor in the
development and growth of hepatocellular carci-
noma, and at the same time it is a marker of recur-
rence and survival of the disease [37].
Recent studies have expressed that the variant of
TRAIL at site 1595 could affect TRAIL gene expression
by changing a potential miRNA binding sequence,
due to 3ʹ-UTR of TRAIL gene may bind both naked
mRNA and mRNA covered RNA proteins and miRNAs
by involved in gene regulation [24,36]. In order to
assess the significance of our results in this way of
thinking, when we analyzed the TRAIL C1595T poly-
morphisms and TRAIL gene expression in NSCLC
patients together, we could not find a statistically
significant association between C1595T variants and
TRAIL gene expression levels. In a study examining
fatty liver disease, it was noted that there was no
effect on gene expression levels of TRAIL gene poly-
morphism in position 1595 [28]. This conclusion on
gene expression of the TRAIL gene polymorphisms of
Yan et al. supports our result.
It has been published that the TRAIL C1595T var-
iant changes in different points of multistage carcino-
genesis, different cancer types and different ethnic
groups in multistage carcinogenesis [21,38].
According to the results of our study, the lower fre-
quency of TRAIL C1595T variant CT genotype in
patients with NSCLC, although not statistically signifi-
cant, suggests that this genotype appears to be a
protective factor in terms of risk of lung cancer.
However, low TRAIL gene expression may be an
important factor in the prognosis and survival of
NSCLC. When we review all our results together, in
revealing the pathogenesis of NSCLC and evaluating
the in terms of prognostic of the disease, it can be
suggested that the TRAIL gene polymorphism and
gene expression levels of our study contain a specific
value. Although TRAIL C1595T variant was not asso-
ciated with disease pathogenesis, TRAIL gene expres-
sion was associated with advanced tumor progression
in our study. This relationship may have influenced
other variants except the TRAIL C1595T variant or this
effect may be regulated by epigenetic mechanisms,
such as mRNAs, independent of TRAIL.
This data will shed light on the future work of
TRAIL to reveal the pathogenesis of NSCLC or to
address with regard to its therapeutic target. Our
study was the first study in which TRAIL C1595T poly-
morphism was evaluated together with TRAIL gene
expression levels in patients with NSCLC and at the
same time TRAIL gene variant carrier was studied for
the first time in Turkish NSCLC cases. Also, we did not
analyze the survival of the patients with regard to
TRAIL polymorphism and expression levels. In order
to be able to evaluate more objectively the data we
have revealed, it is necessary to continue to work by
expanding the number of patient samples. However,
in the future, as well as examining other SNPs belong-
ing to TRAIL gene, it is aimed to determine TRAIL
gene expression levels by immunohistochemical and
cytogenetic tests in different cell lines and to reveal its
effects.
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